CD26/DPP4 Levels in Peripheral Blood and T Cells in Patients With Type 2 Diabetes Mellitus
CD26/DPP4 Levels in Peripheral Blood and T Cells in Patients With Type 2 Diabetes Mellitus
复制标题
DOI：
10.1210/jc.2012-4288
复制
发表时间：
2013-06-01
影响因子：
5.8
通讯作者：
Lee, Dae Ho
中科院分区：
文献类型：
--
作者：
Lee, Sang Ah;Kim, Young Ree;Lee, Dae Ho
内容：二肽基肽酶4（CD 26/DPP 4）在血液T细胞上表达，也以可溶性形式循环目的：探讨2型糖尿病（T2 DM）患者外周血T细胞和循环CD 26/DPP 4水平及其与代谢指标的关系。我们检测了CD 26/DPP 4的表达，（使用流式细胞术的CD 26（+）细胞百分比），血清CD 26/DPP 4水平和活性，以及未接受DPP 4抑制剂治疗的T2 DM患者的各种代谢参数（n = 148）。结果：与健康对照组相比，T2 DM患者外周血CD 4（+）T细胞和CD 8（+）T细胞上CD 26/DPP 4的表达明显增高。仅当排除二甲双胍和/或噻唑烷二酮治疗的T2 DM患者时，T2 DM患者的血清CD 26/DPP 4水平和酶活性也高于对照组;二甲双胍和/或噻唑烷二酮治疗的T2 DM患者的数值低于其他T2 DM患者。通过多变量分析，T2 DM患者的各种参数与T细胞上的CD 26/DPP 4表达（血红蛋白A1 c）、血清sCD 26/DPP 4（通过更新的稳态模型评估评估的血红蛋白A1 c和胰岛素抵抗）和血清CD 26/DPP 4活性（通过更新的稳态模型评估的胰岛素抵抗、γ-谷氨酰转移酶和丙氨酸氨基转移酶）相关。在药物初治的T2 DM患者（n = 50）中，血糖控制12周后，血T细胞上的CD 26/DPP 4表达显著降低。结论：我们的研究结果表明，血T细胞上的CD 26/DPP 4水平与T2 DM患者的血糖控制状态相关。
Context: Dipeptidyl peptidase 4 (CD26/DPP4) is expressed on blood T cells and also circulates in a soluble form (sCD26/DPP4).Objective: We aimed to evaluate blood T cell and circulating CD26/DPP4 and its association with metabolic parameters in patients with type 2 diabetes mellitus (T2DM).Designs: We measured CD26/DPP4 expression (percentage of CD26(+) cells using flow cytometry) on CD4(+) and CD8(+) T cells, serum CD26/DPP4 level and activity, and various metabolic parameters in T2DM patients not on DPP4 inhibitor therapy (n = 148). Nondiabetic subjects (n = 50) were included as a control group.Results: Compared with the healthy controls, CD26/DPP4 expression on CD4(+) T cells and CD8(+) T cells was higher in T2DM patients. Serum CD26/DPP4 levels and enzymatic activities were also higher in patients with T2DM than in the control group only when metformin and/or thiazolidinedione-treated T2DM patients were excluded; metformin and/or thiazolidinedione-treated T2DM patients had lower values compared with other T2DM patients. Various parameters in T2DM patients were related to CD26/DPP4 expression on the T cells (hemoglobin A1c), serum sCD26/DPP4 (hemoglobin A1c and insulin resistance assessed by updated homeostasis model assessment), and serum CD26/DPP4 activity (insulin resistance assessed by updated homeostasis model assessment, gamma-glutamyl transferase, and alanine aminotransferase) by multivariate analyses. After active glucose control for 12 weeks in drug-naive T2DM patients (n = 50), CD26/DPP4 expression on blood T cells was significantly decreased.Conclusions: Our results suggest that the CD26/DPP4 level on blood T cells was associated with glucose control status in patients with T2DM.